




**VERY EARLY ONSET IBD IN CHILDREN**  
 - CAUSES, CURES, & CONUNDRUMS -

Scott B. Snapper, M.D., Ph.D.



STATE OF THE ART RESEARCH LECTURE  
 October 9<sup>th</sup>, 2015  
 NASPGHAN Post-Graduate Course  
 Washington DC





[www.veoibd.org](http://www.veoibd.org)

---

---

---

---

---

---

---

---

### Disclosures

I have the following financial relationships to disclose:

**Abbvie** – IBD Advisory Board; **Cubist** – IBD Advisory Board; **Eisai** - IBD Advisory Board; **Enterome** – IBD Advisory Board; **Hoffman La-Roche** – IBD Advisory Board, Consultant; **Ironwoods** – IBD Advisory Board; **Janssen** – IBD Advisory Board, Consultant; **Lycera** - IBD Advisory Board; **Merck** – Inflammation Advisory Board; **Pfizer** – Therapeutic Scientific Advisory Board; Grant Support; **Synlogic** – IBD Advisory Board

*\* No products or services produced by these companies are relevant to my presentation.*

---

---

---

---

---

---

---

---

### Learning Objectives

- Review immunodeficiencies that may present with intestinal inflammation
- Understand the phenotype, genetics and prognosis for IBD presenting in very young children
- Learn an appropriate immunological evaluation of a child with early IBD.

---

---

---

---

---

---

---

---

**Key Point 1:**

IBD is a Complex Disorder that May Require a Genetically Susceptible Host with an Appropriate Environmental Trigger(s)

**Key Point 2:**

IBD Results from an Exaggerated Mucosal Immune Response to Commensal Microorganisms

**Pathogenesis of IBD**

**Incidence of IBD is Increasing Dramatically Worldwide**

www.veoibd.org Sartor, Nature Clin Prac, 2006

---

---

---

---

---

---

---

---

**Genetics and IBD in the Adult and Pediatric Population**

- Increased risk of IBD in 1<sup>st</sup> degree relatives (26 fold increase for CD; 9 fold increase for UC)
- 30% of children have one or more family members with IBD
- Concordance rate much greater in monozygotic vs dizygotic twins
  - 10-15% in UC; 25-30% in Crohn's

Loftus et al., Gastroenterol. 2004  
Bengtson et al. J. Crohn's Colitis 2009  
Brant., IBD J. 2011  
Ruemmele Curr Opin Gastroenterol 2010

---

---

---

---

---

---

---

---

**GWAS Studies Have Identified over 180 Inflammatory Bowel Disease Susceptibility**

Lees C W et al. Gut doi:10.1136/gut.2009.

---

---

---

---


---

---

---

---

## Key Pathways Arising From Gene Discovery In Crohn's Disease And Ulcerative Colitis



Lees C W et al. Gut doi:10.1136/gut.2009

## Unique Aspects of Pediatric IBD

- ~20% of IBD presents in children
- Children with UC – more extensive disease
- Children with CD – upper intestinal tract involvement common
- Young children often present with Crohn's colitis with perianal involvement

Mamula P. Am J Gastro 2002  
Heyman MB J Pediatr 2005

## Unique Clinical Features of VEO-IBD\*

### VEO - IBD

- Colonic involvement - 80% at < 10 years of age
- Ileal involvement - less common at age < 10 yrs
- Family history – 40-50%
- Extension of disease – up to 40%

### Adolescent and Adult-Onset IBD

- Colonic involvement - <20%
- Ileal involvement – up to 80%
- Family history – 14-20%
- Extension of disease – up to 16%

\* Defined as Age < 10 by the Paris Classification

Griffiths (2004) Best Pract Res Clin; Heyman et al (2005) J Ped; Ruemmele et al (2006) JPGN; Kappelman et al (2008) IBD; Louis et al (2008) Gastro; van Limbergen et al (2008) Gastro; Vernier-Massouille (2008) Gastro; Levine et al (2011) IBD; de Bie et al (2012) IBD

## Unique Aspects of Infantile IBD (< 2yo)

- Often isolated Colonic Disease
- Severe Course – refractory to multiple immunosuppressant medications, often requiring surgery, occasionally fatal
- > 40 % with one or more family members with IBD
- 25% first manifestation of underlying immunodeficiency

Ruemmele 2006 JPGN  
Cannioto 2009 EJP  
Heyman 2005 J Ped

## Greatest Increase in IBD Incidence Very Early Onset IBD

Age at diagnosis	Percent Change in Incidence (P-value by Poisson Regression)		
	IBD	CD	UC
6mo-4yr	+56.8% (P=0.11)	+51.0% (P=N/A)*	+38.1% (P=0.95)
5-9 yr	+65.7% (P<0.0001)	+58.9% (P=0.0003)	+57.9% (P<0.0001)
10-14 yr	+34.1% (P<0.0001)	+36.3% (P=0.002)	+38.9% (P=0.09)
15-17 yr	+25.1% (P=0.009)	+12.1% (P=0.006)	+27.4% (P=0.03)


\* By Poisson regression analysis, controlling for sex

 www.neopics.org

Benchimol et al (2009) Gut 48:1490-97;  
Benchimol et al (2014) Gastro ePub Jun 18.

## Primary Immunodeficiencies Often Present with Intestinal Inflammation

- IPEX syndrome
  - Frequent enteropathy
- Wiskott-Aldrich syndrome
  - 10% with colitis
- Chronic granulomatous disease
  - Gastric granulomas
  - Crohn's-like colitis
- NEMO (NF- $\kappa$ B Essential Modulator) Deficiency
  - enterocolitis
  - superficial cryptitis
- XIAP (X-linked inhibitor of apoptosis)
  - severe fistulizing perianal disease in about 20% of patients
- Common variable immunodeficiency
  - Frequent enteropathy



Estimated Prevalence of Monogenetic Disorder that Can Present with an IBD like immunopathology

Holm Uhlig Gut 2013

monogenic oligogenic polygenic

Pediatric-Onset IBD

Environment

Adult-Onset IBD

Genetics

Familial

AGE

Infantile and VEO-IBD  
Not Captured?

Since these are Rare Diseases an International Effort is Required to Advance our Understanding

*Adapted from Kaser A, Zeissig S & Blumberg RS, Dig Dis 2010*

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

## Case

- Presented in 1<sup>st</sup> year of life with severe colitis
- Persian ancestry
- Multiple enterocutaneous fistulae, recurrent folliculitis, recurrent infections, impaired wound healing



Severe Colitis



Perianal disease with multiple fistulas




Joint effusions



Folliculitis


Glocker, Snapper, Grimbacher, Klein NEJM 2009

## Genetic Evaluation Identified Mutation in IL-10 Receptor



## IL10R Pathway


- IL10 restricts excessive immune responses
- Inhibits secretion of pro-inflammatory cytokines
- IL10 Receptor has two subunits:
  - Alpha – IL10
  - Beta – IL10, -22, -26
- Acts through JAK1, TYK2, and STAT3
- IL10, TYK2, and STAT3 have been identified in IBD GWAS



Shouval, Muise, Snapper, Adv. Immunol. 2013

### IL10R Deficiency Results in Infantile-Onset IBD

- IL10RB and IL10RA mutations have now been found in numerous locations within each gene – to date each having similar presentations and similar signaling defects



- Hematopoietic stem cell therapy can be curative

Glocker, EO. Klein, C. NEJM. 2009; EO Glocker Lancet 2010; B Begue Am J Gastro 2011; Moran CJ, et al, IBD Journal 2012; Engelhardt et al, J Allergy Clin Immunol. 2013.

### Case 2 – IS THIS ONLY RELEVANT TO VEOIBD?

- Patient presented with severe diarrhea and perianal fistulas in first weeks of life → diagnosed with IBD
- Didn't respond to various immunosuppressive medications
- Colectomy at age 5 years
- Severe perianal fistulizing disease persisted




Shouval DS, JPGN, 2014

### CG – Clinical Presentation

- At age 12 years presented with 2 months of abdominal pain and enlarged liver and spleen
- CT – multiple focal liver lesions; hypermetabolic on PET
- Biopsy – Large B cell lymphoma
- Responded well to chemo but relapsed after 3 years
- Awaiting **autologous** stem cell transplant






---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---


---

---


---




## Macrophages (M $\phi$ ) Can Differentiate into Pro and Anti-inflammatory Subsets




## Reduction of Anti-inflammatory M $\phi$ in the Intestine of *Il10rb*<sup>-/-</sup> Mice



## Reduction of Anti-inflammatory M $\phi$ in the Bone Marrow of *Il10rb*<sup>-/-</sup> Mice



## Transfer of WT Macrophages (M2r) Prevents Colitis in *Il10r* mice



Shouval DS, Immunity 2014

## Animal Models Informing Human Studies

Patient	Age of Onset (months)	Current age (months)	<i>IL10R</i> mutation	Clinical features
1	3	48	<i>IL10RB</i> c.*C52T (3' UTR)	Colitis, perianal abscesses, arthritis, folliculitis
2	<1	130	<i>IL10RA</i> c.525delT p.S196fs	Colitis, perianal abscesses, folliculitis, recurrent respiratory infections
3	<2	154	<i>IL10RB</i> c.477G>A p.W159X	Colitis, perianal and renal abscesses, folliculitis, arthritis
4	<8	31	<i>IL10RB</i> g.17030_22177 del5148	Colitis, perianal abscesses, folliculitis
5	<1	184	<i>IL10RB</i> c.278A>C p.S58R / c.1170>A p.W202X	Colitis, perianal abscesses, B cell lymphoma
6	2	3	<i>IL10RB</i> c.114G>A p.W3X	Colitis, recto-vaginal abscess
7	3	21	<i>IL10RB</i> c.438-604del167 p.Y59_D110del (Aexon3)	Colitis, perianal abscesses




Courtesy of Laurie Conklin




Is Mφ generation and function abnormal in these patients ?

Shouval DS, Immunity 2014

## IL-10R Signaling is Required for the Generation and Function of Human Anti-inflammatory Mφ



## IL-10R-Signals in Macrophages Regulate Intestinal Inflammation




---

---

---

---

---

---

---

---

## Developing Gene Therapy Approaches for VEOIBD

Dror Shouval, MD  
Sandra Frei, Ph.D.  
Jeremy Goettel, Ph.D.  
Christian Brendel, PHD  
David Williams, MD PHD

---

---

---

---


---

---

---

---

## Preclinical Model of IL10RB Gene Therapy




---

---

---

---


---

---


---

---

### Transduction of *Il10rb<sup>-/-</sup>* Bone Marrow Precursors With IL10RB Expressing Lentiviral Vectors Protect Mice from Colitis



### Transduction of *Il10rb<sup>-/-</sup>* Bone Marrow Precursors With IL10RB Expressing Lentiviral Vectors Protect Mice from Colitis



## Case 2

- Patient ET
  - Presented at 2 months of age:
  - Blood in stool
  - Diagnosed with cow's milk protein allergy
- Diagnosed < 1 yo with Crohn's colitis.
- Developed perianal and small bowel disease < 2 years of age.
- No evidence of chronic infections or immunodeficiency.
- No family history of IBD, parents not consanguineous.
- Has abnormal low normal reactive oxygen species (ROS) production (3x).



All images are used with the permission of the patient and family

Muise, et al Gut, 2011

### Hypothesis:

**Defects in the NADPH oxidase genes that do not cause overt Chronic Granulomatous Disease (CGD) are associated with susceptibility to IBD.**

Muise, et al Gut, 2011

### NADPH Oxidase Genes and CGD


Gene	Inheritance	Frequency
CYBB: gp91phox	X-Linked Recessive	~65%
CYBA: p22phox	Autosomal Recessive	<5%
NCF1: p47phox	Autosomal Recessive	~25%
NCF2: p67phox	Autosomal Recessive	~5%
NCF4: p40phox	Autosomal Recessive	< 1%



Lam et al., 2010


### Sequencing of NADPH Oxidase Genes in Infantile and VEO-IBD Patients Identifies Deleterious Mutations

- Identified a novel NCF2 variant - (c.113 G/A) resulting in a mutation in p67phox R38Q
- Variant results in aberrant Rac2 binding
- Patient responded to antibiotic treatment
- Examined this mutation – 2 independent VEO-IBD cohorts
  - 4% of VEO-IBD patients (11/268)
  - 0.3% of older IBD patients (1/330)
  - 0.2% of healthy controls (1/480)



Muise, et al Gut, 2011  
Dhillon et al. Gastro 2014

## How do we assess the heritability of the remaining fraction?



- IL10RA (n = 5)
- IL10RB (n = 7)
- unknown (n = 71)

1. Deep sequencing of GWAS loci for identification of rare variants
2. Immunochip analysis of selected genes in similar cohort
3. Whole Exome Sequencing (WES)/Whole Genome Sequencing (WGS)

WES in VEO-IBD patient leads to identification of mutation in XIAP

Exome Sequencing Analysis Reveals Variants in Primary Immunodeficiency Genes in Patients With Very Early Onset Inflammatory Bowel Disease

Dissecting Allele Architecture of Early Onset IBD Using High-Density Genotyping

EA Worthey *Genetics in Medicine* 2011  
Kelsen JR et al, *Gastro* 2015  
Cutler, Kugathason et al, *PLOS ONE* 2015

---

---

---

---

---

---

---

---



---

---

## Case 3 – WES

### Multiple Intestinal Atresia (MIA), SCID and Apoptotic Enterocolitis

- A female patient born at term
  - Unrelated parents
  - Presented with high output secretory hematochezia af birth
  - Lymphopenia and hypogammaglobulinemia
- Colonoscopy demonstrated
  - chronic inflammation with severe friability
  - sloughed mucosa within the colonic lumen
  - crypt apoptosis** and exploding crypts
- WES


---

---

---

---

---

---

---

---

---

---

<b>Mutations in Tetratricopeptide Repeat Domain 7A Result in a Severe Form of Very Early Onset Inflammatory Bowel Disease</b> Yaron Avitzur, <sup>1,2,3,4</sup> Conghui Guo, <sup>1,2</sup> Lucas A. Mastropaslo, <sup>5</sup> Ehsan Bahrami, <sup>1</sup> Hannah Chen, <sup>6</sup> Zhen Zhao, <sup>1</sup> Abdul Eladri, <sup>1,2,3</sup> Sandeep Dhillon, <sup>1</sup> Ryan Murchio, <sup>1</sup> Ramal Fatouh, <sup>1</sup> Hien Huynh, <sup>1</sup> Jennifer L. Walker, <sup>2</sup> Paul W. Wales, <sup>2</sup> Ernest Cutz, <sup>2</sup> Yoshi Kakuta, <sup>1,2</sup> Joel Dudley, <sup>1</sup> Jochen Kammermeier, <sup>1,2</sup> Fiona Powrie, <sup>1,2</sup> Neil Shah, <sup>1,2</sup> Christoph Walz, <sup>1,2</sup> Michaela Nathrath, <sup>1,2</sup> Daniel Kottarz, <sup>1,2</sup> Jacob Puchalski, <sup>1</sup> Jonathan R. Krieger, <sup>1</sup> Tomas Racek, <sup>4</sup> Thomas Kirchner, <sup>1,2</sup> Thomas D. Walters, <sup>2,3</sup> John H. Brunell, <sup>1,2,3</sup> Anne M. Griffiths, <sup>2,3</sup> Nimra Hazzazi, <sup>1,2,3</sup> Parisa Rashtian, <sup>1,2</sup> Mehdi Najari, <sup>1,2</sup> Maryam Monasemzadeh, <sup>1,2</sup> Stephen Pissone, <sup>1,2</sup> Dermot P. B. McGovern, <sup>1,2</sup> Holm H. Uhlig, <sup>1,2</sup> Eric Schadt, <sup>1,2</sup> Christoph Klein, <sup>1,2,3</sup> Scott B. Snapper, <sup>1,2,3,4</sup> and Alekio M. Mushi, <sup>1,2,3,4</sup>		Gastroenterology 2014
JACI 2013	<b>Whole-exome sequencing identifies tetratricopeptide repeat domain 7A (TTC7A) mutations for combined immunodeficiency with intestinal atresias</b> Rui Chen, PhD, <sup>1*</sup> Silvia Giliani, PhD, <sup>2,3*</sup> Gaetano Lanzetta, PhD, <sup>4</sup> George I. Mias, PhD, <sup>5</sup> Silvia Lenardi, BS, <sup>6</sup> Kerry Dobbs, BS, <sup>6</sup> John Marsh, MD, <sup>7</sup> Hyoung In, PhD, <sup>8</sup> Jennifer E. Gallagher, PhD, <sup>7</sup> Douglas H. Phares, PhD, <sup>9</sup> Gloria Eskinchen, PhD, <sup>9</sup> Philipp Lammert, PhD, <sup>10</sup> Kathi Bettiger, MS, <sup>11</sup> Daniele Morante, PhD, <sup>12</sup> Katar Wolinski, MD, <sup>13</sup> Daniele Morante, MD, <sup>14</sup> Eleonora Gallo, MD, <sup>15</sup> Giovanna Mangili, MD, <sup>16</sup> Fuhua Porta, MD, <sup>17</sup> Lucia D. Natarangelo, MD, <sup>18</sup> Stefano Padellini, MD, <sup>19</sup> Waleed Al-Haz, MD, <sup>20</sup> Waleed Al-Haz, MD, <sup>21</sup> Anne Marie Corneau, PhD, <sup>22</sup> Russell E. Traister, MD, PhD, <sup>23</sup> Bing-Yun Fu, MD, <sup>24</sup> Grazia Corallo, PhD, <sup>25</sup> Paolo Faccini, MD, <sup>26</sup> Karl C. Reuter, MD, PhD, <sup>27</sup> Michael Snyder, PhD, <sup>28</sup> and Luigi D. Natarangelo, MD <sup>29</sup>	
JCI 2014	<b>TTC7A mutations disrupt intestinal epithelial apicobasal polarity</b> Amélie E. Bergeron, <sup>1,2,3</sup> Herve F. Pons, <sup>4</sup> Rossana Lembo, <sup>1,2,3</sup> Nader Mahdavi, <sup>1,2</sup> Nathalie Lambert, <sup>1</sup> Marine G. Amarger-Schulz, <sup>1</sup> Pierre Philippot, <sup>1</sup> Patricia Schreiner, <sup>1</sup> Tara G. Abrahamson, <sup>1</sup> Kristin Dymov, <sup>1</sup> G. Christian Lysé-Bergeron, <sup>1</sup> Emmanuelle Lefebvre, <sup>1,2,3,4</sup> Brigitte Monseau-Messart, <sup>1</sup> Dominique Bernatchez, <sup>1</sup> Christine Bibe-Feytaud, <sup>1</sup> Patricia Nadeau, <sup>1</sup> Nicole Bruneau, <sup>1</sup> Alain Fischer, <sup>1,2,3</sup> Hans Clevers, <sup>5</sup> and Genevieve de Saint Basile, <sup>1,2,3,4</sup>	
JMG 2013	<b>Exome sequencing identifies mutations in the gene TTC7A in French-Canadian cases with hereditary multiple intestinal atresia</b> Mark E. Samuels, <sup>1</sup> Jacki Majewski, <sup>1</sup> Najmah Alimoglu, <sup>1</sup> Isabel Fernandez, <sup>1,2</sup> Fernan Casals, <sup>1</sup> Natalie Pans, <sup>1</sup> Helene Deslauriers, <sup>1</sup> Isabelle Gosselin, <sup>1</sup> Elie Haddad, <sup>1,2</sup> Anne Hodgkinson, <sup>1</sup> Youssef Jajouh, <sup>1</sup> Valerie Marchand, <sup>1,2</sup> Jacques I. Michaud, <sup>1,2</sup> Marc-André Rodrigue, <sup>1</sup> Sylvie Desjardins, <sup>1</sup> Stéphane Dubois, <sup>1</sup> Herve de Saint Basile, <sup>1,2</sup> Philip Aschella, <sup>1,2</sup> Vincent Raymond, <sup>1,2</sup> Bruno Mounoud, <sup>1</sup>	

---

---

---

---

---

---

---

---

---

---

## TTC7A Mutations Cause Apoptotic Enterocolitis

- Little is known about the function of the Tetratricopeptide Repeat Domain 7 (*TTC7A*) gene
- Studies suggest it plays a critical role in PI4KIII $\alpha$  regulation
- Defects in murine *Ttc7* gene
  - result in the flaky skin (*fsn*) mutant mice
  - develop pleiotropic abnormalities, including runting syndrome, anemia, psoriasis, diarrhea, and intestinal apoptosis

---

---

---

---

---


---

---

---

## Conclusions: TTC7A-Deficiency and VEOIBD

- Severe intestinal inflammatory process likely at least partially driven by a primary epithelial defect
- Associated with multiple intestinal atresia (and recurs post-resection)
- Associated with SCID (severe combined immunodeficiency)
- Intestinal disease seems to not respond to hematopoietic stem cell transplant




---

---

---

---

---

---

---

---

## Case 4

- Pulm:
  - Bronchiectasis; Pulmonary nodules
  - rec. sinusitis, rec. URTI
- Heme:
  - Autoimmune **thrombocytopenia** & hemolytic **anemia**
  - Infiltration of BM by CD8 $^+$  $\gamma\delta$  T cells
- CNS
  - Seizures
  - Infiltrative lymphocytic lesions
- GI
  - Enteropathy
  - Increased lamina propria and intra-epithelial lymphocytes

Dascha Weir/Alan Leichtner

---

---

---

---

---

---

---

---

# GI Manifestations

- Presented at age 12
- Inflammation of upper & lower GI tract
- Biopsies – villous atrophy, crypt hyperplasia and absent Paneth and goblet cells, increased enterocyte apoptosis and lymphocytic inflammation
- Resistant to 5ASA, steroids, 6-MP, rituximab, prograf, cyclophosphamide, infliximab & sirolimus; Dependent on PN
- Recurrent C. difficile colitis and recurrent herpes zoster infections
- Passed away at age 22 - MRSA sepsis

Zeissig S; Gul 2014

- 
- 
- 
- 
- 
- 

# Identification of *CTLA4* Mutations

Immune dysregulation in human subjects with heterozygous germline mutations in *CTLA4*

See also Kuehn, J. *Immunity* (2009) 30, 1011–1022; Elmes R, Heathcote J, Jolly S, Némethy Z, Anand R, Anand V, et al. *Immunity* (2009) 30, 1023–1034; Zeng H, et al. *Immunity* (2009) 30, 1035–1046; Zeng H, et al. *Immunity* (2009) 30, 1047–1058; Zeng H, et al. *Immunity* (2009) 30, 1059–1070; Zeng H, et al. *Immunity* (2009) 30, 1071–1082; Zeng H, et al. *Immunity* (2009) 30, 1083–1094; Zeng H, et al. *Immunity* (2009) 30, 1095–1106; Zeng H, et al. *Immunity* (2009) 30, 1107–1118; Zeng H, et al. *Immunity* (2009) 30, 1119–1130; Zeng H, et al. *Immunity* (2009) 30, 1131–1142; Zeng H, et al. *Immunity* (2009) 30, 1143–1154; Zeng H, et al. *Immunity* (2009) 30, 1155–1166; Zeng H, et al. *Immunity* (2009) 30, 1167–1178; Zeng H, et al. *Immunity* (2009) 30, 1179–1190; Zeng H, et al. *Immunity* (2009) 30, 1191–1202; Zeng H, et al. *Immunity* (2009) 30, 1203–1214; Zeng H, et al. *Immunity* (2009) 30, 1215–1226; Zeng H, et al. *Immunity* (2009) 30, 1227–1238; Zeng H, et al. *Immunity* (2009) 30, 1239–1250; Zeng H, et al. *Immunity* (2009) 30, 1251–1262; Zeng H, et al. *Immunity* (2009) 30, 1263–1274; Zeng H, et al. *Immunity* (2009) 30, 1275–1286; Zeng H, et al. *Immunity* (2009) 30, 1287–1298; Zeng H, et al. *Immunity* (2009) 30, 1299–1310; Zeng H, et al. *Immunity* (2009) 30, 1311–1322; Zeng H, et al. *Immunity* (2009) 30, 1323–1334; Zeng H, et al. *Immunity* (2009) 30, 1335–1346; Zeng H, et al. *Immunity* (2009) 30, 1347–1358; Zeng H, et al. *Immunity* (2009) 30, 1359–1370; Zeng H, et al. *Immunity* (2009) 30, 1371–1382; Zeng H, et al. *Immunity* (2009) 30, 1383–1394; Zeng H, et al. *Immunity* (2009) 30, 1395–1406; Zeng H, et al. *Immunity* (2009) 30, 1407–1418; Zeng H, et al. *Immunity* (2009) 30, 1419–1430; Zeng H, et al. *Immunity* (2009) 30, 1431–1442; Zeng H, et al. *Immunity* (2009) 30, 1443–1454; Zeng H, et al. *Immunity* (2009) 30, 1455–1466; Zeng H, et al. *Immunity* (2009) 30, 1467–1478; Zeng H, et al. *Immunity* (2009) 30, 1479–1490; Zeng H, et al. *Immunity* (2009) 30, 1491–1502; Zeng H, et al. *Immunity* (2009) 30, 1503–1514; Zeng H, et al. *Immunity* (2009) 30, 1515–1526; Zeng H, et al. *Immunity* (2009) 30, 1527–1538; Zeng H, et al. *Immunity* (2009) 30, 1539–1550; Zeng H, et al. *Immunity* (2009) 30, 1551–1562; Zeng H, et al. *Immunity* (2009) 30, 1563–1574; Zeng H, et al. *Immunity* (2009) 30, 1575–1586; Zeng H, et al. *Immunity* (2009) 30, 1587–1598; Zeng H, et al. *Immunity* (2009) 30, 1599–1610; Zeng H, et al. *Immunity* (2009) 30, 1611–1622; Zeng H, et al. *Immunity* (2009) 30, 1623–1634; Zeng H, et al. *Immunity* (2009) 30, 1635–1646; Zeng H, et al. *Immunity* (2009) 30, 1647–1658; Zeng H, et al. *Immunity* (2009) 30, 1659–1670; Zeng H, et al. *Immunity* (2009) 30, 1671–1682; Zeng H, et al. *Immunity* (2009) 30, 1683–1694; Zeng H, et al. *Immunity* (2009) 30, 1695–1706; Zeng H, et al. *Immunity* (2009) 30, 1707–1718; Zeng H, et al. *Immunity* (2009) 30, 1719–1730; Zeng H, et al. *Immunity* (2009) 30, 1731–1742; Zeng H, et al. *Immunity* (2009) 30, 1743–1754; Zeng H, et al. *Immunity* (2009) 30, 1755–1766; Zeng H, et al. *Immunity* (2009) 30, 1767–1778; Zeng H, et al. *Immunity* (2009) 30, 1779–1790; Zeng H, et al. *Immunity* (2009) 30, 1791–1802; Zeng H, et al. *Immunity* (2009) 30, 1803–1814; Zeng H, et al. *Immunity* (2009) 30, 1815–1826; Zeng H, et al. *Immunity* (2009) 30, 1827–1838; Zeng H, et al. *Immunity* (2009) 30, 1839–1850; Zeng H, et al. *Immunity* (2009) 30, 1851–1862; Zeng H, et al. *Immunity* (2009) 30, 1863–1874; Zeng H, et al. *Immunity* (2009) 30, 1875–1886; Zeng H, et al. *Immunity* (2009) 30, 1887–1898; Zeng H, et al. *Immunity* (2009) 30, 1899–1910; Zeng H, et al. *Immunity* (2009) 30, 1911–1922; Zeng H, et al. *Immunity* (2009) 30, 1923–1934; Zeng H, et al. *Immunity* (2009) 30, 1935–1946; Zeng H, et al. *Immunity* (2009) 30, 1947–1958; Zeng H, et al. *Immunity* (2009) 30, 1959–1970; Zeng H, et al. *Immunity* (2009) 30, 1971–1982; Zeng H, et al. *Immunity* (2009) 30, 1983–1994; Zeng H, et al. *Immunity* (2009) 30, 1995–2006; Zeng H, et al. *Immunity* (2009) 30, 2007–2018; Zeng H, et al. *Immunity* (2009) 30, 2019–2030; Zeng H, et al. *Immunity* (2009) 30, 2031–2042; Zeng H, et al. *Immunity* (2009) 30, 2043–2054; Zeng H, et al. *Immunity* (2009) 30, 2055–2066; Zeng H, et al. *Immunity* (2009) 30, 2067–2078; Zeng H, et al. *Immunity* (2009) 30, 2079–2090; Zeng H, et al. *Immunity* (2009) 30, 2091–2102; Zeng H, et al. *Immunity* (2009) 30, 2103–2114; Zeng H, et al. *Immunity* (2009) 30, 2115–2126; Zeng H, et al. *Immunity* (2009) 30, 2127–2138; Zeng H, et al. *Immunity* (2009) 30, 2139–2150; Zeng H, et al. *Immunity* (2009) 30, 2151–2162; Zeng H, et al. *Immunity* (2009) 30, 2163–2174; Zeng H, et al. *Immunity* (2009) 30, 2175–2186; Zeng H, et al. *Immunity* (2009) 30, 2187–2198; Zeng H, et al. *Immunity* (2009) 30, 2199–2210; Zeng H, et al. *Immunity* (2009) 30, 2211–2222; Zeng H, et al. *Immunity* (2009) 30, 2223–2234; Zeng H, et al. *Immunity* (2009) 30, 2235–2246; Zeng H, et al. *Immunity* (2009) 30, 2247–2258; Zeng H, et al. *Immunity* (2009) 30, 2259–2270; Zeng H, et al. *Immunity* (2009) 30, 2271–2282; Zeng H, et al. *Immunity* (2009) 30, 2283–2294; Zeng H, et al. *Immunity* (2009) 30, 2295–2306; Zeng H, et al. *Immunity* (2009) 30, 2307–2318; Zeng H, et al. *Immunity* (2009) 30, 2319–2330; Zeng H, et al. *Immunity* (2009) 30, 2331–2342; Zeng H, et al. *Immunity* (2009)

---

---

---

---

---

---

# What is CTLA-4 ?

- Suppressive immunoregulatory surface protein
- Activation of T naive cells induces expression of CTLA4 → binds CD80 or CD86 → inhibitory signal to activated T cells
- Shares homology to CD28

The diagram illustrates the role of CTLA-4 in T cell activation and regulation. It shows three scenarios of T cell interaction with an Antigen Presenting Cell (APC):

- Scenario 1:** An APC (blue oval) presents an antigen (red oval) to a T cell (orange oval) via MHC (blue oval). The T cell's CD28 receptor (red) binds to B7 (red) on the APC. This interaction leads to 'Apoptosis / Anergy'.
- Scenario 2:** An APC (blue oval) presents an antigen (red oval) to a T cell (orange oval) via MHC (blue oval). The T cell's CD28 receptor (red) binds to B7 (red) on the APC. The T cell's CTLA-4 receptor (blue) also binds to B7 (red) on the APC. This interaction leads to 'Proliferation / Differentiation / Effector function'.
- Scenario 3:** An APC (blue oval) presents an antigen (red oval) to a T cell (orange oval) via MHC (blue oval). The T cell's CTLA-4 receptor (blue) binds to B7 (red) on the APC. This interaction leads to 'Cell-cycle arrest'.


Source: Nature Reviews | Immunology

- 
- 
- 
- 
- 
- 






## CTLA4 Deficiency



## Immunological Analysis of Patients with CTLA4 Mutations



## Immunologic And Genetic Evaluation

- All patients with low immunoglobulin levels
- Thrombocytopenia, Hemolytic anemia
- Fewer regulatory T cells; markedly fewer naïve T cells; many activated T cells
- Autosomal dominant inheritance; Incomplete penetrance

**Treatment: ? BMT**

**Not all patients young! Some diagnosed in 40's**

## Conclusions – When to suspect CTLA4 Mutations ?

- Multiple autoimmune features
- Low immunoglobulins
- Pulmonary/CNS involvement
- Positive family history

---

---

---

---


---

---

---

---

## LRBA Mutations Can Initially Present as VEO-IBD +/- CVID



Serwas NK; IBD 2015

**LPS-responsive beige-like anchor (LRBA) gene mutation in a family with inflammatory bowel disease and combined immunodeficiency**  
Lopez-Herrera G; Am J Hum Gen 2012; Alangari A; JACI 2012

---

---

---

---

---


---

---

---

## Extended Spectrum of LRBA Deficiency

- Not all have low immunoglobulins
- Report of a family with IPEX-like phenotype




---

---

---

---


---

---

---

---





---

---

---

---

---

---

## VEO-IBD: Take Home Points

- GWAS have shown that genetics in **adult** and **adolescent** pediatric IBD overlap considerably.
- Immunodeficiencies account for a significant percentage of patients presenting with infantile IBD
- Unique genetic abnormalities may be more dominant in VEO-IBD (e.g., IL-10R; NCF2); however, data is limited
- Whole exome sequencing (and ultimately whole genome sequencing) will greatly expand our ability to detect rare variants in individual patients

---

---

---

---

---

---

## Acknowledgements



---

---

---

---

---

---

## Acknowledgements

### Boston Children's Hospital

**Athos Bousvaros**  
**Jeremy Goettel**  
**Dror Shouval/Sandra Frei/ Bruce Horwitz**  
**Jodie Ouahed**, Leslie Grushkin-Lerner  
 Amlan Biswas/James Canavan  
**Liza Konnikova**/Naresh Reddu/Yu-Hui Kang/  
 Michael Field/ Shelby Friel/Alex Griffith/Raj Anand  
 Julia Bender Sterne/Meaghan Foster/

### Christian Brendel/David Williams

**Dr. von Hauner Children's Hospital: Ludwig**  
**Maximilians University Munich**

### **Christoph Klein**

Daniel Kottarz  
 Sibylle Koletzko



### Oxford

Holm Uhlig/Floana Powrie



**Boston Children's Hospital**  
**Early Childhood IBD**  
**Initiative**



[www.veoibd.org](http://www.veoibd.org)

### Hospital for Sick Children

### **Aleixo Muise**

**Yaron Avitzur/Sandeep Dhillon**

### **Abdul Elkadri**

Conghui Guo

Ziad Al-adham

Ryan Murchie

Lucas Mastropaolo

Karoline Fiedler

Anne Griffiths

Thomas Walters



### Mount Sinai Medical Center

Eric Schadt

Judy Cho

### Children's Hospital of Eastern

Ontario

**Eric Benchimol**



Thanks to the patients and 250 scientists at > 80 Centers around the world

**Leslie Grushkin-Lerner, Ph.D.**  
**Program Manager, Boston**



[www.veoibd.org](http://www.veoibd.org)

**Karoline Fiedler**  
**Program Manager, Toronto**

## Very Early Onset IBD Consortium



### Principal Investigators

**Scott B. Snapper, MD, PhD**  
 Wolpov Family Chair in IBD Treatment and Research  
 Director, IBD Center, Boston Children's Hospital  
 Director, IBD Research, Brigham & Women's Hospital

**Aleixo Muise, MD, PhD**  
 Co-Director, IBD Centre  
 Staff Scientist, Hospital for Sick Children  
 University of Toronto

**Christoph Klein, MD, PhD**  
 Chair, Department of Pediatrics,  
 Ludwig-Maximilians-University Munich,  
 Germany

### Founding Investigators

- **Judy Cho**  
 Ruth Ward-Coleman Professor in Translational Genetics, Medicine  
 and Gastroenterology, Vice-Chair, Genetics and Gastroenterology,  
 Mount Sinai School of Medicine, NYC
- **Hans Clevers**  
 Director of the Hubrecht Institute, Utrecht, The Netherlands
- **Lynn Goldman**  
 Dean, School of Public Health and Health Services, George  
 Washington University, DC
- **Dermot McGovern**  
 Director, Translational Medicine, Inflammatory Bowel Disease  
 Center and Immunobiology Research Institute, Cedars Sinai  
 Hospital, LA
- **Ruslan Medzhitov**  
 Professor of Immunobiology; Investigator, Howard Hughes Medical  
 Institute, Yale University

- **Josef Penninger**  
 Senior Scientist and Scientific Director, Institute of Molecular  
 Biotechnology, Austria
- **Fiona Powrie**  
 Chair in Gastroenterology, Head of Nuffield Department of  
 Medicine – Experimental Medicine, University of Oxford
- **David Relman**  
 Professor, Department of Microbiology & Immunology, Stanford  
 University School of Medicine, CA
- **Eric Schadt**  
 Chair of the Department of Genetics and Genomics Sciences,  
 Director of the Institute for Genomics and Multiscale Biology,  
 Mount Sinai School of Medicine, NYC
- **Dan Turner**  
 Head of the Pediatric Gastroenterology and Nutrition Unit at  
 Shaare Zedek Hospital, Jerusalem, Israel

[www.veoibd.org](http://www.veoibd.org)

63




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

### IPEX: (immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome)

- Due to loss-of-function mutation in *FOXP3* (critical for regulatory T cells)
- Autoimmune enteropathy, eczema, type-1 diabetes, elevated IgE
- Often fatal in the first 2 years of life
- *Foxp3*<sup>−/−</sup> mice also develop systemic inflammation, autoimmunity, and premature death

used with permission with permission

---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---

### Increased mortality and multisystem organ failure in IPEX(huDR1) mice



Goettl et al, Blood 2015

### Summary

- huDR1 mice exhibit greater T cell diversity, T cell recall responses, B cell maturation, and antibody class switching compared to NSG mice.
- CD34<sup>+</sup> HSCs from a patient with IPEX syndrome cause multi-organ inflammation, development of autoantibodies, and increased mortality in huDR1 mice similar to that observed in *Foxp3*<sup>sf</sup> mice.

### Future directions

- Evaluate CD34<sup>+</sup> HSCs from very-early onset IBD patients (e.g., IL10R deficiency, Wiskott-Aldrich syndrome, CGD) in huDR1 mice.
- We have re-derived huDR1 mice into germ free conditions to evaluate the role of specific microbes, byproducts, and metabolites in regulating mucosal immune function and promoting homeostasis.